Cancer and COVID-19: Resources for Patients and Survivors

Preparing for Your Next Clinic Visit

Dr. Marshall explains procedures MedStar and Georgetown have instituted to ensure your safety while you receive the best care possible

View Q&A with Dr. Marshall

Current Clinical Trials

Search our current GI clinical trials offered through the MedStar Georgetown Cancer Institute

View Clinical Trials

New Colon Cancer Concerns

Dr. Marshall talks with Today Show about why colon cancer is on the rise in young patients

View Today Show Segment with Dr. Marshall

Summer of Support Drive

Please help us keep the momentum going with a generous gift of any size today to our Summer of Support Drive!

More information

Dr. John L. Marshall addresses some of the questions he and his Georgetown Lombardi colleagues have been hearing most often from current cancer patients and survivors. Learn More

Gastrointestinal (GI) Cancers are the most common and most fatal of all cancers. The Ruesch Center will re-focus national efforts on curing this deadly set of diseases.

Justice Ruth Bader Ginsburg says she is being treated for recurrence of cancer

July 20th, 2020

“The treatment she is getting is typical for pancreatic cancer. That would fit,” said John L. Marshall, director of the Ruesch Center for the Cure of Gastrointestinal Cancers at Georgetown Lombardi Comprehensive Cancer Center. “But her cancer history is very unusual, from a good perspective. She’s always done much better than one would have anticipated.”

Practice-Changing GI Cancer Highlights From Virtual ASCO 2020

July 7th, 2020

Dr. John Marshall shares his personal highlights of GI cancers research from this year’s ASCO conference. There were a lot of important, practice-changing data and he touches on some big-picture themes that are really starting to hit home in GI cancer.

Sign Up to receive all Ruesch updates directly in your Inbox

We will deliver our quarterly newsletter, monthly updates and other announcements to your Inbox with information on upcoming special events, current clinical trials and cutting edge research and trends in the GI cancer field.